Vancomycin Dosing in Augmented Renal Clearance
A 34-year-old man weighing 82 kg with no prior comorbidities is admitted with MRSA bacteremia from an infected prosthetic knee. Serum creatinine is 0.5 mg/dL (eGFR by CKD-EPI ~150 mL/min/1.73 m²), consistent with augmented renal clearance. He is hemodynamically stable. The team starts vancomycin 15 mg/kg IV every 12 hours (1,250 mg q12h). On day 3, a trough drawn 30 minutes before the 7th dose is 6.2 mcg/mL. The infectious diseases consultant recommends targeting an AUC24/MIC of 400–600 assuming MIC 1 mcg/mL. The pharmacy has AUC-estimation software but the night shift lacks access until morning, and the patient has now missed no doses but has had two subtherapeutic levels. Nephrology is consulted about whether the creatinine is 'falsely low.'
1. Interpret the trough and explain why standard weight-based q12h dosing is failing in this patient. What pharmacokinetic parameter is the dominant driver here?
Read the worked answer
A trough of 6.2 mcg/mL is far below the 10–15 mcg/mL surrogate for AUC 400–600 and confirms under-exposure. In augmented renal clearance (ARC), creatinine is not 'falsely low' - it reflects genuinely high glomerular filtration, and vancomycin clearance is almost entirely renal. With eGFR ~150, the elimination rate constant is roughly doubled versus normal, so a 12-hour interval allows drug to fall to near-nadir before the next dose. The dominant driver is renal clearance (CL), not volume of distribution: Vd is near normal (~0.7 L/kg), so the problem is interval/clearance, not loading. The teaching point: standard 15 mg/kg q12h assumes CrCl ~60–90; in ARC the same mg/kg produces a short half-life and low AUC. Options include shortening the interval (q8h) and/or increasing dose, guided by AUC.
2. The software is unavailable overnight. Propose a defensible interim regimen adjustment and monitoring plan, and state what you would NOT do.
Read the worked answer
Interim approach without AUC software:
- Do not simply raise the dose while keeping q12h - that widens peak-trough swing and risks trough-driven nephrotoxicity without reliably raising AUC.
- Shorten the interval toward q8h (e.g., 1,250 mg q8h) to raise trough/AUC in a high-clearance patient, since the half-life is short and accumulation is limited.
- Obtain a steady-state trough before the 4th dose on the new regimen (after ~3–4 half-lives), plus a peak if feasible, and compute a two-level AUC estimate manually (trapezoidal or first-order equations) as a bridge until software is available.
- Monitor renal function daily and reassess as clearance changes with clinical course (sepsis resolution lowers CL). What NOT to do: do not give a large loading dose to 'catch up' (Vd is not expanded), do not extend the interval, and do not accept a single low trough as adequate exposure - the AUC target, not the trough, is the endpoint.